Disclosures for "Adult Patients' Experiences With Selumetinib Treatment Versus Placebo for Neurofibromatosis Type One-Plexiform Neurofibroma Associated Symptoms and Their Impacts: A Qualitative Sub-study of a Phase Three, Placebo-controlled Trial (KOMET)"
-
Dr. Swampillai has received personal compensation in the range of $0-$499 for serving as a market research with Adivo Associates.
-
Dr. Blanco has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Blanco has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SpringWorks. The institution of Dr. Blanco has received research support from Asociació Catalana Neurofibromatosis (AcNefi). The institution of Dr. Blanco has received research support from Spanish Health Ministry.
-
Dr. Barnett Tapia has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Barnett Tapia has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD pharma. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Barnett Tapia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. The institution of Dr. Barnett Tapia has received research support from Department of defense. The institution of Dr. Barnett Tapia has received research support from Muscular dystrophy canada. The institution of Dr. Barnett Tapia has received research support from MgNet. The institution of Dr. Barnett Tapia has received research support from NIH. The institution of Dr. Barnett Tapia has received research support from Cartesian. The institution of Dr. Barnett Tapia has received research support from Alexion. Dr. Barnett Tapia has received intellectual property interests from a discovery or technology relating to health care.
-
Miss Lee has nothing to disclose.
-
Dr. Mastronuzzi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen.
-
Prof. Matthies has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific. Prof. Matthies has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion/ Astra Zeneca. Prof. Matthies has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boston Scientific. The institution of Prof. Matthies has received research support from German Research Council.
-
Prof. perrotta has nothing to disclose.
-
Dr. Eoli has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion.
-
The institution of Dr. Shuhaiber has received research support from SPRINGWORKS . The institution of Dr. Shuhaiber has received research support from RECURSION . The institution of Dr. Shuhaiber has received research support from AstraZeneca. The institution of Dr. Shuhaiber has received research support from CTF. The institution of Dr. Shuhaiber has received research support from NFLECTION .
-
Dr. Adeyemi has received personal compensation for serving as an employee of Alexion. Dr. Adeyemi has or had stock in Alexion.
-
Dr. Doughton has received personal compensation for serving as an employee of AstraZeneca. An immediate family member of Dr. Doughton has received personal compensation for serving as an employee of AstraZeneca. Dr. Doughton has stock in AstraZeneca. An immediate family member of Dr. Doughton has stock in AstraZeneca.
-
Dr. de la Rosa Rodriguez has received personal compensation for serving as an employee of Alexion. Dr. de la Rosa Rodriguez has stock in Astrazeneca.
-
Dr. Farschtschi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion Pharma. Dr. Farschtschi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for SpringWorks Therapeutics. The institution of Dr. Farschtschi has received research support from Bundesverband Neurofibromatose Germany. The institution of Dr. Farschtschi has received research support from Nothing is Forever e.V. Germany.